1. 102PHGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. (25th November 2018) Authors: Suzuki, K; Yuki, S; Nakano, S; Kawamoto, Y; Nakatsumi, H; Hatanaka, K; Ando, T; Furukawa, K; Ishiguro, A; Ohta, T; Eto, K; Nakajima, J; Nakamura, M; Sogabe, S; Kato, K; Tateyama, M; Kato, S; Sekiguchi, M; Sakata, Y; Komatsu, Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 103PHGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib. (25th November 2018) Authors: Tsuji, Y; Yuki, S; Sawada, K; Muranaka, T; Kobayashi, Y; Okuda, H; Ogawa, K; Minami, S; Honda, T; Dazai, M; Kato, T; Sasaki, T; Shindo, Y; Ota, S; Sato, A; Ueda, A; Saitoh, S; Nagai, H; Sakata, Y; Komatsu, Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 107PPhase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results. (25th November 2018) Authors: Kagawa, Y; Satake, H; Kato, T; Oba, K; Yasui, H; Nakamura, M; Watanabe, T; Hirata, K; Muro, K; Komatsu, Y; Yoshino, T; Yamazaki, K; Mishima, H; Kotaka, M; Tsuji, A; Kakeji, Y; Oki, E; Nagata, N; Junichi, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 110PHGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction. (25th November 2018) Authors: Ishiguro, A; Yuki, S; Nakano, S; Kawamoto, Y; Sawada, K; Tsuji, Y; Honda, T; Miyagishima, T; Yoshida, S; Hatanaka, K; Sasaki, T; Muto, O; Ohnuma, H; Kato, S; Sato, A; Abe, M; Kato, K; Amano, T; Sakata, Y; Komatsu, Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 115PHGCSG1301: A multicenter, double-blind, randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment. (25th November 2018) Authors: Dazai, M; Yuki, S; Sawada, K; Muranaka, T; Kawamoto, Y; Nakatsumi, H; Nakano, S; Ishiguro, A; Tateyama, M; Sato, A; Kobayashi, Y; Nakamura, M; Okuda, H; Takahashi, Y; Eto, K; Muto, S; Hatanaka, K; Amano, T; Sakata, Y; Komatsu, Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 132PLiposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC). (24th November 2019) Authors: Ioka, T; Nakamori, S; Sugimori, K; Kanai, M; Ikeda, M; Ozaka, M; Furukawa, M; Okusaka, T; Kawabe, K; Furuse, J; Komatsu, Y; Sato, A; Shimizu, S; Chugh, P; Tang, R; Ueno, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 164PMulti-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502). (24th November 2019) Authors: Sasaki, Y; Muranaka, T; Kawamoto, Y; Sawada, K; Nakatsumi, H; Harada, K; Miyagishima, T; Hatanaka, K; Dazai, M; Ueda, A; Sasaki, T; Shinada, K; Tsuji, Y; Yuki, S; Sakamoto, N; Nishimoto, N; Sakata, Y; Komatsu, Y Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 166PThe comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study. (24th November 2019) Authors: Sasaki, T; Nakano, S; Yuki, S; Sawada, K; Muranaka, T; Kawamoto, Y; Nakatsumi, H; Ando, T; Yoshita, H; Harada, K; Kobayashi, Y; Miyagishima, T; Hatanaka, K; Tanimoto, A; Ishiguro, A; Honda, T; Dazai, M; Komatsu, Y Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 168PA retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS). (24th November 2019) Authors: Honda, T; Nakano, S; Yuki, S; Sawada, K; Muranaka, T; Kawamoto, Y; Nakatsumi, H; Yoshita, H; Ando, T; Harada, K; Kobayashi, Y; Miyagishima, T; Hatanaka, K; Tanimoto, A; Ishiguro, A; Dazai, M; Sasaki, T; Komatsu, Y Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 195PHGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC). (24th November 2019) Authors: Tanimoto, A; Yagisawa, M; Nakano, S; Kawamoto, Y; Yuki, S; Ishiguro, A; Takahata, T; Sato, A; Iwanaga, I; Ehira, N; Uebayashi, M; Muto, O; Sasaki, T; Hatanaka, K; Tateyama, M; Wakabayashi, T; Dazai, M; Minami, S; Sakata, Y; Komatsu, Y Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗